In , Sun Pharma Advanced Research Company Ltd (Pharma - Others) is outperforming Nifty 500 with +25.7% relative strength. Fundamentals: Very Weak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -47% | -45% | Inflection Down |
| PAT (Net Profit) | 0% | -31% | Stable |
| OPM | -670.0% | -17600 bps | Volatile |
Based on publicly available financial data. This is educational research, not investment advice.
Sun Pharma Advanced Research Company Ltd's latest quarterly results (Dec 2025) show
Sun Pharma Advanced Research Company Ltd's profit is declining with an stable trend.
Sun Pharma Advanced Research Company Ltd's revenue growth trend is inflecting downward.
Sun Pharma Advanced Research Company Ltd's operating margin is volatile.
Sun Pharma Advanced Research Company Ltd's long-term compounding rates
Sun Pharma Advanced Research Company Ltd's earnings growth is stable with mixed signals on a sequential basis.
Sun Pharma Advanced Research Company Ltd's trailing twelve month (TTM) performance
Sun Pharma Advanced Research Company Ltd is rated Very Weak with a fundamental score of 19/100. This score is calculated from objective financial metrics
Sun Pharma Advanced Research Company Ltd has a debt-to-equity ratio of N/A.
Sun Pharma Advanced Research Company Ltd's return ratios over recent years
Sun Pharma Advanced Research Company Ltd's operating cash flow is negative (FY2025).
Sun Pharma Advanced Research Company Ltd currently does not pay a significant dividend (yield 0.00%).
Sun Pharma Advanced Research Company Ltd's shareholding pattern (Mar 2026)
Sun Pharma Advanced Research Company Ltd's promoter holding has remained stable recently.
Sun Pharma Advanced Research Company Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Sun Pharma Advanced Research Company Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Based on quantitative research signals, here is why Sun Pharma Advanced Research Company Ltd may be worth studying
Sun Pharma Advanced Research Company Ltd investment thesis summary:
Sun Pharma Advanced Research Company Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
